Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Driscoll has maintained an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $41 to $42.
February 27, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Driscoll has reaffirmed an Outperform rating on Revolution Medicines and raised the price target from $41 to $42.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100